REG - Oncimmune Hldgs PLC - Notice of Half Year Results

Oncimmune HoldingsAnnouncement

25/02/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220225:nRSY7626Ca&default-theme=true

RNS Number : 7626C  Oncimmune Holdings PLC  25 February 2022

25 February 2022

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Notice of Half Year Results

 

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, will be announcing its half year results for the six months ended 30
November 2021 on 28 February 2022.

 

Analyst and investor presentation

 

Dr Adam M Hill, Chief Executive Officer, together with Matthew Hall, Chief
Financial Officer, will host a live presentation of the results, via Investor
Meet Company, at 15.00 GMT.

 

·      The online presentation will be open to all existing shareholders
and potential new investors.

 

·      Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9am GMT the day before the meeting or at any time
during the live presentation. Responses to the Q&A will be published at
the earliest opportunity on the Investor Meet Company platform.

 

·      Investor feedback can also be submitted directly to management
immediately following the event.

 

Access to Investor Meet Company is free and interested parties can register to
attend the presentation via the following link:
https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
(https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor)

 

Attendees who have already registered on the Investor Meet Company platform to
meet the Company will automatically receive an invitation to the presentation.

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organisations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research centre in Dortmund, Germany. The business platform enables
life science organisations to optimise drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS Commercial team is based in the US and Europe and Oncimmune
is seeking to replicate the Dortmund facility in the US in the medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programmes, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBUGDDXUDDGDS